CellBion Co., Ltd. (KOSDAQ:308430)

Market Cap	242.90B
Revenue (ttm)	2.63B
Net Income (ttm)	-7.43B
Shares Out	12.83M
EPS (ttm)	-665.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,346
Average Volume	438,121
Open	19,480
Previous Close	19,540
Day's Range	19,120 - 19,690
52-Week Range	9,930 - 29,600
Beta	n/a
RSI	57.18
Earnings Date	Nov 13, 2025

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 57
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308430

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.